Evidence map›Paper›PMID 36818928›Full record

ArticleActa clinica Croatica2022

PENTRAXIN 3 LEVELS CORRELATE WELL WITH DISEASE SEVERITY AT ADMISSION IN COVID-19 PATIENTS.

Mehmet Emirhan Işık, Ramazan Korkusuz, Gülçin Erdal Şahingöz, Arzu Cennet Işık, Ali Karagöz, Nilgün Işıksaçan, Sevgi Kalkanlı Taş, Kadriye Kart Yaşar

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta clinica Croatica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Mehmet Emirhan IşıkUniversity of Health Sciences, Koşuyolu High Specialization Research and Training Hospital, Department of Infectious Diseases, Istanbul, Turkey.
Ramazan KorkusuzUniversity of Health Sciences, Bakırköy Dr. Sadi Konuk Research and Training Hospital, Department of Infectious Diseases, Istanbul, Turkey.
Gülçin Erdal ŞahingözUniversity of Health Sciences, Bakırköy Dr. Sadi Konuk Research and Training Hospital, Department of Internal Medicine, Istanbul, Turkey.
Arzu Cennet IşıkUniversity of Health Sciences, Kartal Dr. Lütfi Kırdar City Hospital, Department of Internal Medicine, Istanbul, Turkey.
Ali KaragözUniversity of Health Sciences, Koşuyolu High Specialization Research and Training Hospital, Department of Cardiology, Istanbul, Turkey.
Nilgün IşıksaçanUniversity of Health Sciences, Bakırköy Dr. Sadi Konuk Research and Training Hospital, Department of Biochemistry, Istanbul, Turkey.
Sevgi Kalkanlı TaşUniversity of Health Sciences, Department of Immunology, Istanbul, Turkey.
Kadriye Kart YaşarUniversity of Health Sciences, Bakırköy Dr. Sadi Konuk Research and Training Hospital, Department of Infectious Diseases, Istanbul, Turkey.
Sağlık Bilimleri Üniversitesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pentraxin 3 (PTX3), a long pentraxin, is not only released from dendritic cells and neutrophils but also from epithelial and endothelial cells such as alveolar epithelium. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) initially activates the innate immune system, causing a complex immune response. Clinical and experimental studies suggest that PTX3, a locally and systemically secreted marker, can be used as a predictor of the severity and mortality in respiratory infections. In the current study, serum PTX3 levels in patients hospitalized with COVID-19 were found to be significantly increased at admission and showed significant association with the disease severity.

Indexed as

COVID-19Endothelial CellsBiomarkersC-Reactive ProteinHumansPatient AcuityPentraxinsSARS-CoV-2BiomarkersC-Reactive ProteinPentraxinsCOVID-19C-reactive proteinInnate immunityPentraxin 3SARS-CoV-2

Identifiers

PMID36818928
PMCPMC9934037
OpenAlexW4319440901

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.